Rajiv S. Shukla has been our Chairman and Chief Executive Officer since inception and has two decades of buyouts, investments and operations experience in the healthcare industry. Mr. Shukla served as Chairman and Chief Executive Officer of Constellation Alpha Capital Corp. (“CNAC”), a Nasdaq-listed special purpose acquisition company, from June 2017 to August 2019. CNAC raised $144 million in proceeds from a Nasdaq initial public offering and successfully closed its initial business combination with DermTech, Inc. in August 2019. Since August 2019, Mr. Shukla has served as an independent director on the board of directors of Ocunexus Therapeutics, a clinical stage biotech company. From June 2013 to May 2015, Mr. Shukla served as Chief Executive Officer of Pipavav Defence & Offshore Engineering Company (now Reliance Defence and Engineering Limited), an Indian listed shipbuilding and defense manufacturing company. In this role, he led the team through an operational restructuring that involved re-alignment of key business areas, several senior hires in the management team, submission of a large amount of new business bids to Indian and international clients and structuring of strategic alliances with global leaders in shipbuilding and defense. At Pipavav, he also successfully implemented a financial restructuring and sold control to the Reliance ADA Group. Between 2008 and 2013, Mr. Shukla worked as an investor at ICICI Venture, Morgan Stanley Investment Management and Citi Venture Capital International. Throughout his investment career, Mr. Shukla has been involved with numerous investments in healthcare companies. As a private equity investor, Mr. Shukla was involved with numerous control and minority healthcare investments and served as a member of the board of directors of I-ven Medicare, a hospital roll-up platform comprising multiple control investments and significant minority stakes in tertiary care hospitals and outpatient treatment centers, Ranbaxy Fine Chemicals Ltd, a roll-up of specialty chemicals and animal health businesses, Swiss Bio, a U.S. based clinical CRO, Bharat Biotech, a vaccine company, three specialty pharma companies: Arch Pharmalabs, Malladi Drugs and Unimark Remedies. From 2001 to 2006, Mr. Shukla served as Senior Director at Pfizer, Inc. (NYSE:PFE). In this role, he played a key role in several acquisitions including Pharmacia in 2003, Meridica in 2004, Vicuron Pharmaceuticals and Idun Pharmaceuticals in 2005, and Rinat Neuroscience in 2006. Mr. Shukla also led the operational integration of these organizations into Pfizer across multiple sites around the world. Mr. Shukla graduated from Harvard University with a Masters in Healthcare Management and Policy and received a Bachelors in Pharmaceutics from the Indian Institute of Technology. We believe Mr. Shukla is well qualified to serve on our board of directors due to his experience as a chief executive officer of two public companies and his experience with control transactions.
Patrick A. Sturgeon has been our Chief Financial Officer since inception and has nearly two decades of experience with M&A and equity capital market transactions in the healthcare and other sectors. He has served as a Managing Director at Brookline Capital Markets, a division of Arcadia Securities, LLC (“Brookline”) since March 2016. At Brookline, Mr. Sturgeon focuses on mergers and acquisitions, public financing, private capital raising, secondary offerings, and capital markets. On the public financing front, he focuses on SPAC transactions, primarily underwritten initial public offerings and initial business combinations. From July 2013 to February 2016, Mr. Sturgeon served as a Managing Director at Axiom Capital Management. He worked at Freeman & Co. from October 2002 to November 2011, where he focused on mergers and acquisitions in the financial services sector. Mr. Sturgeon received his B.S. in Economics from the University of Massachusetts, Amherst and his M.B.A in Finance from New York University.
Terrance L. Carlson will serve as one of our directors as of the effective date of the registration statement of which this prospectus forms a part. Mr. Carlson is a lawyer and consultant who has held several key positions in the healthcare field. He has served as Chief Legal Officer of Woven Orthopedic Technologies, LLC since April 2013. Mr. Carlson served as a Senior Vice President and as General Counsel for Mallinckrodt Pharmaceuticals from June 2015 to March 2018, Synthes, Inc. from June 2010 to July 2012, Medtronic, Inc. from 2004 to 2009, and PerkinElmer, Inc. from 1999 to 2004. Mr. Carlson served as Chairman of the Investment Committee of Gerchen Keller Capital LLC, a litigation finance fund, from March 2013 to December 2016. He previously served as Deputy General Counsel for Allied Signal (now Honeywell International) and as an associate and partner at Gibson, Dunn & Crutcher LLP. Mr. Carlson holds a J.D. from the University of Michigan and a B.S.B.in Accounting from the University of Minnesota. We believe Mr. Carlson is well qualified to serve on our board of directors due to his experience as General Counsel of multiple listed companies in the medical devices and pharmaceutical sectors.
Brian Robertson will serve as one of our directors as of the effective date of the registration statement of which this prospectus forms a part. Mr. Robertson currently serves as the Founder, Chairman and Chief Executive Officer of VisiQuate, Inc, a cloud-based data analytics company focused on serving many of America’s most respected healthcare organizations, since it was founded in August 2009. Previously, Mr. Robertson was Co-Founder of MedeAnalytics where he served in various positions including Chief Operating Officer, Chief Technology Officer and Chief Innovation Officer from February 2001 to February 2009. He served as Founder and President of Impact Receivables Group from March 1997 to January 2001 where he worked with various healthcare providers to improve their revenue cycle management, accounting and compliance operations. Mr. Robertson holds a B.S. from California State University and Masters in Health Services Administration from St. Mary’s College, California. We believe Mr. Robertson is well qualified to serve on our board of directors due to his experience as chief executive officer of two healthcare analytics companies.
Bruce A. Springer will serve as one of our directors as of the effective date of the registration statement of which this prospectus forms a part. Mr. Springer has served as Chairman and Chief Executive Officer of Prolucent Health, a technology enabled healthcare services company focused on connecting clinical workers with healthcare employers across all employment types, since it was founded in September 2019. Previously, he served as CEO and President of OneHealth Solutions, a technology enabled behavioral health company, from October 2012 until September 2014 when it was acquired by Viverae. He served as Chief Executive Officer and President of Transaction Wireless from February 2008 until December 2010 when it was acquired by FirstData. Mr. Springer served as CEO and President of BidShift/Concerro from June 2003 until December 2006 when it was acquired by API Healthcare. Mr. Springer served as Managing Partner of GreenSpring Ventures, a venture fund based in Atlanta from June 2000 until May 2003. From February 1997 to May 2000, Mr. Springer served as Executive Vice President/Chief Operating Officer of WebMD, a pioneer in technology enabled healthcare services. Mr. Springer currently serves as an independent director of PatientPoint, LLC since July 2017, and Advisor to BetterNight since June 2017 and to Sleep Data, LLC since March 2018. From June 2007 to November 2019, Mr. Springer served as Healthcare Advisor to Francisco Partners, a private equity firm focused on investments in technology and technology-enabled services businesses with approximately $13 billion in assets under management. Previously, he served as an independent director and advisor to Avadyne Health (acquired by MTS Health) from May 2013 to April 2016, API Healthcare (acquired by General Electric) from November 2008 to July 2013, AdvancedMD (acquired by Automatic Data Processing) from August 2007 to November 2008. Mr. Springer holds a B.S. in Marketing from Purdue University. We believe Mr. Springer is well qualified to serve on our board of directors due to his experience as chief executive officer of four healthcare technology companies and as a healthcare advisor to a private equity fund.
Kevin Xie, Ph.D. will serve as one of our directors as of the effective date of the registration statement of which this prospectus forms a part. Dr. Xie has served as Chief Financial Officer of Gracell Biotechnologies, an immune cell therapy company focused on cancer, since July 2020. Previously, Dr. Xie served as President of Healthcare Holdings for Fosun Group, a Chinese international conglomerate and investment company, and Chief Representative of Fosun, NY from 2015 to 2020. Since August 2019, Dr. Xie has served as an advisor to Flare Capital, a healthtech venture fund formed in partnership with several healthcare companies. From February 2012 to March 2015, Dr. Xie served as Managing Partner for Kinglington Capital, an investment company. He co-founded and served as Portfolio Manager for Locust Walk Capital from April 2010 to February 2012. From January 2009 to January 2010, Dr. Xie served as Healthcare Sector Head for Scopia Capital, a global hedge fund. From 2005 to 2008, he served as Principal and subsequently Managing Director for Great Point Partners, a healthcare hedge fund. Dr. Xie served as an Equity Analyst for Delaware Investments, an asset management firm, from June 2002 to July 2005. From 1999 to 2001, he served as Project Leader and Senior Scientist for Boehringer Ingelheim Pharmaceuticals, Inc. Dr. Xie holds a B.S. from Tianjin University in China, a Ph.D. from The City University in New York, and an M.B.A. from The Wharton School, University of Pennsylvania. We believe Dr. Xie is well qualified to serve on our board of directors due to his experience as a public equity and private equity investor in numerous healthcare companies.